Tocilizumab in MOG-antibody spectrum disorder: a case report

G. Novi, M. Gastaldi, D. Franciotta, G. Pesce, L. Benedetti, A. Uccelli

Research output: Contribution to journalArticle

Abstract

Background: Myelin oligodendrocyte glycoprotein antibody-related spectrum disorders (MOG-SD) are a heterogeneous group of inflammatory demyelinating diseases of the central nervous system, usually responsive to conventional immunosuppressive therapies. However, knowledge about treatment of non-responder patients is scarce. Methods: We report on a 20-year-old MOG-SD patient who experienced clinical deterioration despite rituximab-induced B-cell depletion. Results: Rescue therapy with tocilizumab (TCZ) prevented further relapses, with reduction of spinal-cord load on MRI, and a remarkable reduction of disability at the two-year follow-up. Conclusion: Our observations suggest that TCZ could induce clinico-radiologic improvements, which make it as an option for the treatment of MOG-SD.

LanguageEnglish
Pages312-314
Number of pages3
JournalMultiple Sclerosis and Related Disorders
Volume27
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Myelin-Oligodendrocyte Glycoprotein
Antibodies
Demyelinating Diseases
Therapeutics
Immunosuppressive Agents
Spinal Cord
B-Lymphocytes
Central Nervous System
Recurrence
tocilizumab

Keywords

  • MOG
  • Neuromyelitis optica spectrum disorders
  • Tocilizumab

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Tocilizumab in MOG-antibody spectrum disorder : a case report. / Novi, G.; Gastaldi, M.; Franciotta, D.; Pesce, G.; Benedetti, L.; Uccelli, A.

In: Multiple Sclerosis and Related Disorders, Vol. 27, 01.01.2019, p. 312-314.

Research output: Contribution to journalArticle

@article{fcb9d8c473b2422bad910f2812c8d6ec,
title = "Tocilizumab in MOG-antibody spectrum disorder: a case report",
abstract = "Background: Myelin oligodendrocyte glycoprotein antibody-related spectrum disorders (MOG-SD) are a heterogeneous group of inflammatory demyelinating diseases of the central nervous system, usually responsive to conventional immunosuppressive therapies. However, knowledge about treatment of non-responder patients is scarce. Methods: We report on a 20-year-old MOG-SD patient who experienced clinical deterioration despite rituximab-induced B-cell depletion. Results: Rescue therapy with tocilizumab (TCZ) prevented further relapses, with reduction of spinal-cord load on MRI, and a remarkable reduction of disability at the two-year follow-up. Conclusion: Our observations suggest that TCZ could induce clinico-radiologic improvements, which make it as an option for the treatment of MOG-SD.",
keywords = "MOG, Neuromyelitis optica spectrum disorders, Tocilizumab",
author = "G. Novi and M. Gastaldi and D. Franciotta and G. Pesce and L. Benedetti and A. Uccelli",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.msard.2018.11.012",
language = "English",
volume = "27",
pages = "312--314",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier",

}

TY - JOUR

T1 - Tocilizumab in MOG-antibody spectrum disorder

T2 - Multiple Sclerosis and Related Disorders

AU - Novi, G.

AU - Gastaldi, M.

AU - Franciotta, D.

AU - Pesce, G.

AU - Benedetti, L.

AU - Uccelli, A.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Myelin oligodendrocyte glycoprotein antibody-related spectrum disorders (MOG-SD) are a heterogeneous group of inflammatory demyelinating diseases of the central nervous system, usually responsive to conventional immunosuppressive therapies. However, knowledge about treatment of non-responder patients is scarce. Methods: We report on a 20-year-old MOG-SD patient who experienced clinical deterioration despite rituximab-induced B-cell depletion. Results: Rescue therapy with tocilizumab (TCZ) prevented further relapses, with reduction of spinal-cord load on MRI, and a remarkable reduction of disability at the two-year follow-up. Conclusion: Our observations suggest that TCZ could induce clinico-radiologic improvements, which make it as an option for the treatment of MOG-SD.

AB - Background: Myelin oligodendrocyte glycoprotein antibody-related spectrum disorders (MOG-SD) are a heterogeneous group of inflammatory demyelinating diseases of the central nervous system, usually responsive to conventional immunosuppressive therapies. However, knowledge about treatment of non-responder patients is scarce. Methods: We report on a 20-year-old MOG-SD patient who experienced clinical deterioration despite rituximab-induced B-cell depletion. Results: Rescue therapy with tocilizumab (TCZ) prevented further relapses, with reduction of spinal-cord load on MRI, and a remarkable reduction of disability at the two-year follow-up. Conclusion: Our observations suggest that TCZ could induce clinico-radiologic improvements, which make it as an option for the treatment of MOG-SD.

KW - MOG

KW - Neuromyelitis optica spectrum disorders

KW - Tocilizumab

UR - http://www.scopus.com/inward/record.url?scp=85056780048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056780048&partnerID=8YFLogxK

U2 - 10.1016/j.msard.2018.11.012

DO - 10.1016/j.msard.2018.11.012

M3 - Article

VL - 27

SP - 312

EP - 314

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

SN - 2211-0348

ER -